Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination

Recently approved vaccines have shown remarkable efficacy in limiting SARS-CoV-2-associated disease. However, with the variety of vaccines, immunization strategies, and waning antibody titers, defining the correlates of immunity across a spectrum of antibody titers is urgently required. Thus, we pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Gorman, Matthew J., Patel, Nita, Guebre-Xabier, Mimi, Zhu, Alex L., Atyeo, Caroline, Pullen, Krista M., Loos, Carolin, Goez-Gazi, Yenny, Carrion, Ricardo, Tian, Jing-Hui, Yuan, Dansu, Bowman, Kathryn A., Zhou, Bin, Maciejewski, Sonia, McGrath, Marisa E., Logue, James, Frieman, Matthew B., Montefiori, David, Mann, Colin, Schendel, Sharon, Amanat, Fatima, Krammer, Florian, Saphire, Erica Ollmann, Lauffenburger, Douglas A., Greene, Ann M., Portnoff, Alyse D., Massare, Michael J., Ellingsworth, Larry, Glenn, Gregory, Smith, Gale, Alter, Galit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405506/
https://www.ncbi.nlm.nih.gov/pubmed/34485950
http://dx.doi.org/10.1016/j.xcrm.2021.100405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405506/
https://www.ncbi.nlm.nih.gov/pubmed/34485950
http://dx.doi.org/10.1016/j.xcrm.2021.100405

Ejemplares similares